ConductScience.org, home

Paper25973333

Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.

Velikyan I and 6 others. Am J Nucl Med Mol Imaging, 2015. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy. Papers, record 25973333. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25973333

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.
PubMed
Journal
Am J Nucl Med Mol Imaging
PubMed
Year
2015
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
1.07
iCite
Revised in PubMed
2023-11-04
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Velikyan IIrina
2Bulenga TNThomas N
3Selvaraju RRamkumar
4Lubberink MMark
5Espes DDaniel
6Rosenström UUlrika
7Eriksson OOlof

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115653658Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.J Nucl Med2005https://conductscience.org/library/papers/15653658PubMed
211340564[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.Int J Cancer2001https://conductscience.org/library/papers/11340564PubMed
39044843Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes.Cancer Res1997https://conductscience.org/library/papers/9044843PubMed
421711223Positron emitting [68Ga]Ga-based imaging agents: chemistry and diversity.Med Chem2011https://conductscience.org/library/papers/21711223PubMed
58455089Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.J Nucl Med1993https://conductscience.org/library/papers/8455089PubMed
622388631Lutetium-labelled peptides for therapy of neuroendocrine tumours.Eur J Nucl Med Mol Imaging2012https://conductscience.org/library/papers/22388631PubMed
711585290[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.Eur J Nucl Med2001https://conductscience.org/library/papers/11585290PubMed
816025254Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.Diabetologia2005https://conductscience.org/library/papers/16025254PubMed
912236780Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody.Bioconjug Chem2002https://conductscience.org/library/papers/12236780PubMed
1016447056Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs.Diabetologia2006https://conductscience.org/library/papers/16447056PubMed
1119585115Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours.Eur J Nucl Med Mol Imaging2009https://conductscience.org/library/papers/19585115PubMed
1219915842Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.Eur J Nucl Med Mol Imaging2010https://conductscience.org/library/papers/19915842PubMed
1317575235[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.Clin Cancer Res2007https://conductscience.org/library/papers/17575235PubMed
1419383333Imaging and cancer: a review.Mol Oncol2008https://conductscience.org/library/papers/19383333PubMed
1518445841Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.J Clin Oncol2008https://conductscience.org/library/papers/18445841PubMed
1621555692Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.J Clin Oncol2011https://conductscience.org/library/papers/21555692PubMed
1724857864Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.Nucl Med Biol2014https://conductscience.org/library/papers/24857864PubMed
1811190491Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.Cancer Biother Radiopharm2000https://conductscience.org/library/papers/11190491PubMed
1923223392Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.J Nucl Med2013https://conductscience.org/library/papers/23223392PubMed
2022768026Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma.Theranostics2012https://conductscience.org/library/papers/22768026PubMed

See all 43 referencesDownload CSV of references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
38708210Nanoassembly-Mediated Exendin-4 Derivatives to Decrease Renal Retention.ACS Omega2024https://conductscience.org/library/papers/38708210PubMed
38195680Carrier systems of radiopharmaceuticals and the application in cancer therapy.Cell Death Discov2024https://conductscience.org/library/papers/38195680PubMed
37265006New Radiolabeled Exendin Analogues Show Reduced Renal Retention.Mol Pharm2023https://conductscience.org/library/papers/37265006PubMed
37242457Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37242457PubMed
37109517Role of Exendin-4 Functional Imaging in Diagnosis of Insulinoma: A Systematic Review.Life (Basel)2023https://conductscience.org/library/papers/37109517PubMed
36431313Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update.J Clin Med2022https://conductscience.org/library/papers/36431313PubMed
35762648Multivalent γ-PGA-Exendin-4 Conjugates to Target Pancreatic β-Cells.Chembiochem2022https://conductscience.org/library/papers/35762648PubMed
35056858Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [68Ga]Ga-NODAGA-Exendin-4 Produced by a Fully Automated Method.Molecules2022https://conductscience.org/library/papers/35056858PubMed
33297381Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.Diagnostics (Basel)2020https://conductscience.org/library/papers/33297381PubMed
33019671Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.Int J Mol Sci2020https://conductscience.org/library/papers/33019671PubMed
31903131Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.Theranostics2020https://conductscience.org/library/papers/31903131PubMed
29335487Increased Expression of GLP-1R in Proliferating Islets of Men1 Mice is Detectable by [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 /PET.Sci Rep2018https://conductscience.org/library/papers/29335487PubMed
28891030Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4.Acta Diabetol2017https://conductscience.org/library/papers/28891030PubMed
28721305Fully automated GMP production of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for clinical use.Am J Nucl Med Mol Imaging2017https://conductscience.org/library/papers/28721305PubMed
28295000Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.Pharmaceuticals (Basel)2017https://conductscience.org/library/papers/28295000PubMed
28067253Whole organ and islet of Langerhans dosimetry for calculation of absorbed doses resulting from imaging with radiolabeled exendin.Sci Rep2017https://conductscience.org/library/papers/28067253PubMed
28025655Targets and probes for non-invasive imaging of β-cells.Eur J Nucl Med Mol Imaging2017https://conductscience.org/library/papers/28025655PubMed
27819034Quantification of β-Cell Mass in Intramuscular Islet Grafts Using Radiolabeled Exendin-4.Transplant Direct2016https://conductscience.org/library/papers/27819034PubMed
27275825Feasibility of Multiple Examinations Using (68)Ga-Labelled Collagelin Analogues: Organ Distribution in Rat for Extrapolation to Human Organ and Whole-Body Radiation Dosimetry.Pharmaceuticals (Basel)2016https://conductscience.org/library/papers/27275825PubMed
27094935In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use.Diabetologia2016https://conductscience.org/library/papers/27094935PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25973333

GET https://conductscience.org/api/papers/v1/25973333/references?page=2